# ALTA-1L (NCT02737501)

> ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02737501
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Ariad Pharmaceuticals
- Conditions: Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma
- Interventions: Brigatinib; Crizotinib
- Enrollment: 275
- Primary outcome: Progression-free Survival (PFS)

## Commentary we found

- Podcasts: 14
- YouTube: 11
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=alta-1l-nct02737501

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02737501", "email": "<work email>"}; the inbox owner confirms by the emailed link.